For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Aragon Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 36

% Expired Patents = 8.3

CIPO Patents = 4

EPO Patents = 20

Forward Citations = 165

Loading Chart...

Loading Chart...

34 inventors (with patents filed for the assignee):

Nicholas D Smith (15 out of 59 patents)

Mark R Herbert (9 out of 13 patents)

Ouathek Ouerfelli (8 out of 29 patents)

4. Isan Chen (8 out of 10 patents)

5. Anna Dilhas (6 out of 10 patents)

6. Celine Bonnefous (5 out of 12 patents)

7. Jackaline Dalgard Julien (5 out of 12 patents)

8. Geert Verreck (3 out of 3 patents)

9. Arturo Molina (3 out of 3 patents)

10. Cyril Ben Haim (3 out of 6 patents)

11. Andras Horvath (3 out of 17 patents)

12. Johan Erwin Edmond Weerts (3 out of 10 patents)

13. Jennifer Albaneze-Walker (3 out of 3 patents)

14. Steven P Govek (2 out of 34 patents)

15. Anna Dihas (2 out of 2 patents)

Core Competencies:

Anticancer Compositions

Anti-Androgens

Androgen Receptor Modulators

Castrate-Resistant Prostate Cancer

Metastatic Castration-Sensitive

Crystalline Forms

Diarylthiohydantoin Compound

Hepatic Impairment

Resistance Determination

Estrogen Receptor Modulators

36 patents: Sort by Forward Citations

1. 12766103 - Anticancer compositions (2026-10-20),

2. 12746230 - Anticancer compositions (2026-09-29),

3. RE50642 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2025-10-21),

4. 12303497 - Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer (2025-05-20),

5. 12303493 - Anticancer compositions (2025-05-20),

6. 12018008 - Crystalline forms of an androgen receptor modulator (2024-06-25),

7. 11963952 - Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer (2024-04-23),

8. 11911511 - Anticancer compositions (2024-02-27),

9. 11723898 - Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment (2023-08-15),

10. RE49353 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2023-01-02),

11. 11491149 - Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer (2022-11-08),

12. 11224575 - Anticancer compositions (2022-01-18),

13. 11160796 - Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer (2021-11-02),

14. 11040953 - Process for the preparation of a diarylthiohydantoin compound (2021-06-22),

15. 10934271 - Crystalline forms of an androgen receptor modulator (2021-03-02),

Company Overview

Aragon Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer and other serious diseases. The company specializes in the discovery and advancement of novel drug candidates that target specific biological pathways, aiming to improve treatment outcomes for patients. With a commitment to scientific excellence, Aragon leverages cutting-edge research and technology to address unmet medical needs and enhance the quality of life for those affected by complex health conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

36 Patents

#174 in San Diego, CA

#2,258 in California

#9,534 in US

#18,777 in the World

San Diego, CA, United States of America

Aragon Pharmaceuticals, Inc.

Forward Citations = 165

34 inventors:

Nicholas D Smith (15 out of 59 patents)

Mark R Herbert (9 out of 13 patents)

Ouathek Ouerfelli (8 out of 29 patents)

4. Isan Chen (8 out of 10 patents)

5. Anna Dilhas (6 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aragon Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/aragon-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…